Caribou Biosciences shares surge 40.50% premarket on positive Phase 1 trial data for vispa-cel and CB-011, showing high efficacy in lymphoma and myeloma.

Caribou Biosciences surged 40.50% in premarket trading following the release of positive Phase 1 trial data for two allogeneic CAR-T therapies. The ANTLER trial for vispa-cel in relapsed/refractory B-cell lymphoma showed an 82% overall response rate (ORR), 64% complete response (CR) rate, and 51% 12-month progression-free survival (PFS), comparable to autologous CAR-T therapies. The therapy demonstrated a favorable safety profile, enabling outpatient administration. Additionally, the CaMMouflage trial for CB-011 in multiple myeloma reported a 92% ORR, 75% ≥CR rate, and 91% MRD negativity in BCMA-naïve patients, with manageable toxicity. CEO Rachel Haurwitz highlighted vispa-cel’s potential as a best-in-class allogeneic CAR-T therapy and outlined plans for a pivotal Phase 3 trial in lymphoma. The data underscored the company’s progress in advancing off-the-shelf cell therapies with strong efficacy and accessibility, aligning with the significant premarket rally.